Evidence map›Paper›PMID 9012838›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1997

Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG.

H Tighe, K Warnatz, D Brinson, M Corr, W O Weigle, S M Baird, D A Carson

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01921413 (Clinical Validation of Fyodor Urine Malaria Test), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01921413 completednot on this mapstarted 2013, after this paper: background citation

Clinical Validation of Fyodor Urine Malaria Test (UMT)

TypeobservationalSponsorFyodor Biotechnologies IncRan2013 to 2014Enrolled1,893ConditionsMalariaArmsUrine Malaria Test
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.Proceedings of the National Academy of Sciences of the United States of America · 2005
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

H TigheDepartment of Medicine, University of California at San Diego, La Jolla 92093-0663, USA.
K Warnatz
D Brinson
M Corr
W O Weigle
S M Baird
D A Carson
Scripps Research Institute · US

Funding

RHEUMATOID FACTOR: GENETICS, PATHOGENESIS, &MODULATIONR01AR025443 · NIAMS · SCRIPPS CLINIC AND RESEARCH FOUNDATION · PI CARSON, DENNIS A · 1986 to 1988
–
RHEUMATOID FACTOR: GENETICS, PATHOGENESIS AND MODULATIONR37AR025443 · NIAMS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI CARSON, DENNIS A · 1989 to 1998
–
REGULATION AND FUNCTION OF RF EXPRESSING CELLSR55AR042153 · NIAMS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI TIGHE, HELEN P · 1995 to 1995
–
NIAMS NIH HHS AR25443NIAMS NIH HHS AR42153
6 · The paper itself

Abstract

Rheumatoid factor (RF) B cells proliferate during secondary immune responses to immune complexed antigen and antigen specific T cells, but higher affinity RFs are not detected except in patients with rheumatoid arthritis and other autoimmune diseases. Consequently, there must exist highly efficient mechanisms for inactivation of these higher-affinity RF B cell clones under normal circumstances. Exposure of transgenic mice expressing a human IgM RF to soluble human IgG in the absence of T cell help causes antigen specific B cell deletion in 2-3 days. The deletion is independent of the Fas/Fas ligand (FasL) pathway of apoptosis and is preceded by a phase of partial activation involving increase in cell size and expression of B7 and ICAM-1, and transient release of low levels of immunoglobulin. Complete B cell activation involving the formation of germinal centers and sustained high level RF secretion only occurs if T cell help is provided simultaneously. RF B cells exposed to tolerogen remain competent to secrete RF in vitro if provided with an appropriate antigenic stimulus and T cell help. Consequently, death of these cells is not preceded by anergy. Abortive activation/deletion of B cells by antigen in the absence of T cell-derived survival signals may represent the major mechanism for maintaining peripheral tolerance in B cells expressing higher affinity RF. The lack of anergy, and the potential for reactivation before death, provide a means for maintaining RF production under pathologic circumstances, such as may occur in the inflamed rheumatoid synovium.

Indexed as

AnimalsApoptosisB-LymphocytesHumansImmune ToleranceImmunoglobulin GImmunoglobulin MLymphocyte ActivationLymphocyte DepletionMiceMice, TransgenicReceptors, Antigen, B-CellRheumatoid FactorSolubilityImmunoglobulin GImmunoglobulin MReceptors, Antigen, B-CellRheumatoid Factor

Identifiers

PMID9012838
PMCPMC19567
OpenAlexW1999412111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.